Currently, PATH shares trade at a significant 40% discount to peers based on EV/Sales and EV/EBITDA multiples. The transition ...

UiPath, Inc. (NYSE:PATH) is one of the cheap AI stocks to buy in 2026. On February 23, 2026, UiPath announced a suite of agentic AI solutions for healthcare providers and payers, targeting ...

These five agentic AI stocks have big potential upside.

UiPath Inc. is rated a strong buy, with a price target near $18, following a 30% sell-off driven by AI-related sector fears. PATH's robust AI-driven automation platform, strong earnings beats, and 16% ...

NEW YORK--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced new agentic AI solutions for the healthcare industry for providers and payers at the ViVE 2026 ...

Detailed price information for Uipath Inc Cl A (PATH-N) from The Globe and Mail including charting and trades.

UiPath announces agentic AI solutions for healthcare revenue cycle management at ViVE 2026, targeting medical records review, claim denials and prior authorization. The company argues that ...

NEW YORK--(BUSINESS WIRE)--UiPath (NYSE: PATH), a global leader in agentic automation, today announced it is expanding its alliance with Deloitte through the launch of Deloitte’s Agentic ERP offering.

Agentic AI is set to become the next big thing in AI. UiPath is uniquely positioned to be an agentic AI orchestration platform. Perhaps the biggest issue with agentic AI is that AI is still prone to ...

Offerings for medical records summarization, claim denial prevention and resolution, and prior authorization streamline payer/provider collaboration and dramatically reduce processing and payment ...